BETHESDA, Md., Nov. 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and...
SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix...
RICHMOND, Calif., May 21 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (NASDAQ:SGMO), a world-leader in the development and commercialization of zinc finger DNA-binding proteins (ZFPs) as...
PALO ALTO, Calif., May 14 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) announced today announced that it has been selected to be included in the NASDAQ Biotechnology...
REDWOOD CITY, Calif., May 14 /PRNewswire-FirstCall/ -- Maxygen, Inc. (NASDAQ:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it will be...
MEMPHIS, Tenn., May 15 /PRNewswire-FirstCall/ -- GTx, Inc. (NASDAQ:GTXI), the Men's Health Biotech Company, announced today that it will be added to the NASDAQ Biotechnology Index(R...
CHESTER, N.J., May 15 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (NASDAQ:ARXT) today announced that it was selected for addition to the NASDAQ Biotechnology Index(R...
NEW YORK, May 12 /PRNewswire-FirstCall/ -- The Nasdaq Stock Market, Inc. ("NASDAQ(R)") (NASDAQ:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology...
BOTHELL, Wash., Nov. 14 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK), a leader in developing therapeutics using advanced molecular biology-based drug delivery...
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- The Nasdaq Stock Market, Inc. ("NASDAQ") (NASDAQ:NDAQ) announced today the results of the semi-annual re- ranking of the NASDAQ Biotechnology Index(R...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales